Li Xia, Hu Youdong, Zhang Fenglin, Chen Ying, Zhou Hualan, Guo Dianxuan, Zhao Qingna
Department of Geriatrics, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu 223002, China.
Oxid Med Cell Longev. 2016;2016:4910829. doi: 10.1155/2016/4910829. Epub 2016 Dec 1.
Unbalanced oxidant and antioxidant status played an important role in myocardial infarction. The present study was a clinical trial combined preclinically with targeted agent against cardiovascular injuries and ischemia in vivo model. We tried to confirm the association of unbalanced oxidant and antioxidant status with coronary chronic total occlusion (CTO) in 399 very old patients (80~89 years) and investigated the potential therapeutic value of purified polysaccharide from endothelium corneum gigeriae galli (PECGGp). We analyzed levels of circulating superoxide dismutase 3 (SOD3), nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and malondialdehyde (MDA) in very old patients with coronary CTO. Levels of SOD3, NO, eNOS, and MDA in the cardiac tissue were measured in myocardial infarction rats. Levels of SOD3, eNOS, and NO were lowered ( < 0.001) and levels of MDA were increased ( < 0.001). PECGGp treatment increased levels of SOD3, eNOS, and NO ( < 0.01) in cardiac tissue, while decreasing levels of MDA ( < 0.01). PECGGp may suppress unbalanced oxidant and antioxidant status in infarcted myocardium by inhibiting levels of MDA and elevating NO, eNOS, and SOD3 levels. PECGGp could be considered as a potential therapeutic agent for coronary CTO in very old patients.
氧化应激与抗氧化状态失衡在心肌梗死中起重要作用。本研究是一项临床试验,临床前结合针对心血管损伤和体内缺血的靶向药物及模型。我们试图在399例80至89岁的高龄患者中证实氧化应激与抗氧化状态失衡与冠状动脉慢性完全闭塞(CTO)的相关性,并研究鸡内金内皮纯化多糖(PECGGp)的潜在治疗价值。我们分析了冠状动脉CTO高龄患者循环中超氧化物歧化酶3(SOD3)、一氧化氮(NO)、内皮型一氧化氮合酶(eNOS)和丙二醛(MDA)的水平。在心肌梗死大鼠中测量心脏组织中SOD3、NO、eNOS和MDA的水平。SOD3、NO、eNOS水平降低(<0.001),MDA水平升高(<0.001)。PECGGp治疗可提高心脏组织中SOD3、eNOS和NO的水平(<0.01),同时降低MDA水平(<0.01)。PECGGp可能通过抑制MDA水平、提高NO、eNOS和SOD3水平来抑制梗死心肌中氧化应激与抗氧化状态的失衡。PECGGp可被认为是高龄患者冠状动脉CTO的一种潜在治疗药物。